TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model

BACKGROUND: Castrate Resistant Prostate Cancer (CRPC) is an advanced disease resistant to systemic traditional medical or surgical castration, and resistance is primarily attributed to reactivation of AR through multiple mechanisms. TMPRSS2-ERG fusions have been shown to regulate AR signaling, inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Semaan, Louie, Mander, Navneet, Cher, Michael L., Chinni, Sreenivasa R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802314/
https://www.ncbi.nlm.nih.gov/pubmed/31638934
http://dx.doi.org/10.1186/s12885-019-6185-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802314/
https://www.ncbi.nlm.nih.gov/pubmed/31638934
http://dx.doi.org/10.1186/s12885-019-6185-0

Ejemplares similares